Total Payments
$134,021
2024 Payments
$28,371
Companies
17
Transactions
104
Medicare Patients
506
Medicare Billing
$63,360
Payment Breakdown by Category
Consulting$93,200 (69.5%)
Other$25,350 (18.9%)
Travel$11,001 (8.2%)
Food & Beverage$4,426 (3.3%)
Education$44.17 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $93,200 | 28 | 69.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,795 | 7 | 10.3% |
| Honoraria | $11,555 | 4 | 8.6% |
| Travel and Lodging | $11,001 | 33 | 8.2% |
| Food and Beverage | $4,426 | 30 | 3.3% |
| Education | $44.17 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $68,875 | 63 | $0 (2024) |
| Currax Pharmaceuticals LLC | $11,303 | 5 | $0 (2024) |
| SANOFI US SERVICES INC. | $10,020 | 8 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $8,545 | 3 | $0 (2018) |
| Neurocrine Biosciences, Inc. | $6,388 | 2 | $0 (2024) |
| ABBVIE INC. | $6,298 | 2 | $0 (2024) |
| Rhythm Pharmaceuticals, Inc. | $5,737 | 5 | $0 (2022) |
| ReShape Lifesciences Inc. | $3,234 | 3 | $0 (2023) |
| PFIZER INC. | $2,856 | 3 | $0 (2019) |
| Medtronic, Inc. | $2,800 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,371 | 13 | Currax Pharmaceuticals LLC ($9,503) |
| 2023 | $4,546 | 4 | ReShape Lifesciences Inc. ($3,234) |
| 2022 | $17,061 | 13 | Novo Nordisk Inc ($9,523) |
| 2021 | $8,708 | 7 | Novo Nordisk Inc ($8,708) |
| 2020 | $7,940 | 3 | Novo Nordisk Inc ($3,740) |
| 2019 | $24,638 | 30 | Novo Nordisk Inc ($21,676) |
| 2018 | $31,801 | 21 | Novo Nordisk Inc ($13,024) |
| 2017 | $10,957 | 13 | Novo Nordisk Inc ($10,859) |
All Payment Transactions
104 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| 12/17/2024 | Neurocrine Biosciences, Inc. | CRENESSITY (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/17/2024 | Neurocrine Biosciences, Inc. | CRENESSITY (Drug) | Travel and Lodging | In-kind items and services | $387.55 | General |
| Category: Neuropsychiatry | ||||||
| 12/06/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,447.50 | General |
| 11/14/2024 | Novo Nordisk Inc | Wegovy (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 11/13/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: Obesity | ||||||
| 11/04/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Food and Beverage | In-kind items and services | $109.27 | General |
| Category: Obesity | ||||||
| 10/11/2024 | Veru Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| 08/20/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Consulting Fee | Cash or cash equivalent | $4,370.00 | General |
| Category: Obesity | ||||||
| 08/05/2024 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 07/24/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Obesity | ||||||
| 05/10/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 05/03/2024 | Veru Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| 11/15/2023 | ReShape Lifesciences Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| 08/15/2023 | ReShape Lifesciences Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,750.00 | General |
| 06/23/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| 06/12/2023 | ReShape Lifesciences Inc. | — | Food and Beverage | Cash or cash equivalent | $83.64 | General |
| 12/14/2022 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $6,885.00 | General |
| 12/14/2022 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $641.84 | General |
| 12/14/2022 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $550.07 | General |
| 12/14/2022 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $368.52 | General |
| 12/14/2022 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $322.50 | General |
| 12/13/2022 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 11/21/2022 | Rhythm Pharmaceuticals, Inc. | Imcivree (Drug) | Honoraria | Cash or cash equivalent | $4,755.00 | General |
| Category: Genetic Disease | ||||||
| 11/21/2022 | Rhythm Pharmaceuticals, Inc. | Imcivree (Drug) | Travel and Lodging | Cash or cash equivalent | $425.20 | General |
| Category: Genetic Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 133 | 141 | $99,409 | $17,611 |
| 2022 | 4 | 146 | 185 | $116,889 | $22,860 |
| 2021 | 5 | 92 | 109 | $54,138 | $11,968 |
| 2020 | 3 | 135 | 173 | $37,122 | $10,921 |
Total Patients
506
Total Services
608
Medicare Billing
$63,360
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 67 | 75 | $47,549 | $9,005 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 55 | 55 | $47,268 | $7,743 | 16.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $4,592 | $862.99 | 18.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 59 | 91 | $56,223 | $11,164 | 19.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 55 | 55 | $45,011 | $8,764 | 19.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 18 | 24 | $9,687 | $1,962 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 15 | $5,968 | $970.27 | 16.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 26 | 37 | $14,324 | $2,911 | 20.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $11,832 | $2,656 | 22.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 20 | $10,797 | $2,500 | 23.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 18 | 18 | $10,615 | $2,357 | 22.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 14 | 18 | $6,570 | $1,543 | 23.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 70 | 103 | $20,480 | $6,938 | 33.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 47 | 52 | $11,180 | $2,282 | 20.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 18 | 18 | $5,462 | $1,701 | 31.1% |
About Dr. Caroline Apovian, M.D
Dr. Caroline Apovian, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346205606.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Caroline Apovian, M.D has received a total of $134,021 in payments from pharmaceutical and medical device companies, with $28,371 received in 2024. These payments were reported across 104 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($93,200).
As a Medicare-enrolled provider, Apovian has provided services to 506 Medicare beneficiaries, totaling 608 services with total Medicare billing of $63,360. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Internal Medicine
- Location Boston, MA
- Active Since 04/19/2006
- Last Updated 09/28/2021
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1346205606
Products in Payments
- Saxenda (Drug) $24,633
- CONTRAVE (Drug) $11,303
- SOTAGLIFLOZIN (Drug) $10,020
- SOLIQUA (Drug) $8,545
- CRENESSITY (Drug) $6,388
- Ozempic (Drug) $6,303
- Imcivree (Drug) $5,707
- FibroScan (Device) $2,500
- SUNOSI (Drug) $1,700
- Wegovy (Drug) $107.83
- Belviq (Drug) $11.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Boston
Dr. Jason Gaglia, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $2.4M
Endocrinology, Diabetes & Metabolism $2.4M
Michael Rosenblatt, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $637,025
Endocrinology, Diabetes & Metabolism $637,025
Dr. Osama Hamdy, M.d., Ph.d, M.D., PH.D
Endocrinology, Diabetes & Metabolism — Payments: $286,677
Endocrinology, Diabetes & Metabolism $286,677
Augusto Caballero-Robles, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $234,576
Endocrinology, Diabetes & Metabolism $234,576
Martin Abrahamson, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $223,325
Endocrinology, Diabetes & Metabolism $223,325
Barbara Kahn, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $197,865
Endocrinology, Diabetes & Metabolism $197,865